Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 5 January 2026 - 6 January 2026

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly shares rose about 1.6% Tuesday after Nimbus Therapeutics announced a deal to develop an oral obesity drug with the company. Nimbus will receive $55 million upfront and could get up to $1.3 billion in total payments plus royalties. The agreement follows Novo Nordisk’s U.S. launch of its $149-a-month Wegovy pill, intensifying focus on oral weight-loss treatments.
6 January 2026
··
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk’s U.S.-listed shares rose 4.7% to $57.71 Tuesday after launching oral Wegovy for self-pay patients at $149 a month for starter doses. The pill is now available at major pharmacies and through telehealth. Investors await early demand data and updates from a key healthcare conference on Jan. 13. Rival Eli Lilly expects a regulatory decision on its own weight-loss pill in March.
6 January 2026
···
Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

Alumis shares surged 129% Tuesday after its psoriasis pill, envudeucitinib, met all main goals in Phase 3 trials. About 65% of patients reached PASI 90 and over 40% achieved complete clearance at week 24. The company reported no new safety concerns and plans to file for FDA approval in the second half of 2026. Traders are watching durability and safety data.
6 January 2026
··
AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

Health Canada approved AbbVie’s Maviret for acute and chronic hepatitis C in adults and children aged 3 and older. AbbVie shares were flat premarket at $220.18 after falling nearly 4% Monday. The approval followed a Priority Review based on Phase 3 data. Investors await AbbVie’s Jan. 14 appearance at the J.P. Morgan Healthcare Conference.
6 January 2026
··
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading after the company launched an oral version of its Wegovy weight-loss drug, priced from $149 a month for some cash-paying patients. The stock traded at $57.29, up from $55.11. Investors are watching early demand and await the company’s February 4 results for margin outlook. The launch comes amid restructuring and job cuts at Novo’s U.S. operations.
6 January 2026
···
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

New York, January 5, 2026, 5:47 PM ET — After-hours Eli Lilly and Co shares fell on Monday and were last down 3.6% at $1,041.51 in after-hours trading. The stock weakened as rival Novo Nordisk began rolling out a pill version of its Wegovy weight-loss drug in the United States. The Washington Post The drop matters because investors have priced Lilly as a long-duration obesity winner, with expectations anchored to rapid growth in demand and tight supply. Any new sign that the market is shifting toward cheaper oral options can force a reset in assumptions about pricing power. GLP-1 drugs,
6 January 2026
···
Merck stock ticks higher as MRK nears recent highs ahead of JPM Healthcare Conference

Merck stock ticks higher as MRK nears recent highs ahead of JPM Healthcare Conference

New York, January 5, 2026, 15:35 EST — Regular session Merck & Co (NYSE:MRK) shares edged up on Monday as investors looked ahead to the drugmaker’s appearance at the annual J.P. Morgan Healthcare Conference next week. The stock was up 0.3% at $106.80 at 3:35 p.m. EST, after earlier reaching $108.30. The conference is a closely watched early-year marker for healthcare stocks, often offering the first public read on management priorities before earnings season ramps up. Merck’s share performance has also been tied to investor confidence in its longer-term growth story, led by the cancer immunotherapy Keytruda and a broader
5 January 2026
··
Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears

Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears

New York, January 5, 2026, 15:22 EST — Regular session Xenon Pharmaceuticals Inc (XENE) shares were down 6.5% at $41.60 in afternoon trading on Monday, about 8% off the session high. The Nasdaq-listed biotech traded between $45.21 and $41.45, with roughly 787,000 shares changing hands. The slide comes with Xenon approaching a busy stretch of investor events and trial milestones ahead of next week’s J.P. Morgan Healthcare Conference, often a tone-setter for biotech trading. Xenon’s lead molecule, azetukalner, is in Phase 3 trials — late-stage studies typically used to support drug-approval filings — in epilepsy and mood disorders, and the
5 January 2026
··
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

New York, January 5, 2026, 14:21 EST — Regular session Shares of Viking Therapeutics (VKTX) slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%. The move highlights how sensitive obesity-drug developers remain to pricing signals from the market leaders. Viking has no approved products, so changes in expected pricing can hit the stock as hard as trial data. Direct-to-consumer discounts are also changing how investors think about margins
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

NEW YORK, Jan 5, 2026, 13:54 EST — Regular session Structure Therapeutics shares fell 7.7% to $62.86 in afternoon trade on Monday, paring an earlier rally and marking another volatile session for the obesity-drug developer. The stock has ranged from $72.02 to $62.50 so far in the regular session. The move came as Novo Nordisk began U.S. sales of a once-daily pill version of Wegovy, bringing a branded oral option into pharmacies at $149 a month for starter doses for self-paying patients, Reuters reported. Novo’s website shows higher-dose pricing at $299 a month, with the 4 mg dose set to
5 January 2026
·····
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

New York, Jan 5, 2026, 13:31 EST — Regular session Arrowhead Pharmaceuticals shares were down about 6.9% on Monday after the company said Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock fell $4.68 to $63.11 after swinging between $60.75 and $70.87. MarketScreener The clearance gives Arrowhead another regulated market for its first commercial product, as investors shift attention from the science to execution. It also keeps the spotlight on how quickly the company can convert approvals into reimbursed prescriptions. The selloff underscored how hard it can be for single-stock catalysts to cut through sector tape.
5 January 2026
···
Abivax stock slides 9% in U.S. trade as biotech weakens; ECCO 2026 looms

Abivax stock slides 9% in U.S. trade as biotech weakens; ECCO 2026 looms

New York, January 5, 2026, 13:03 EST — Regular session Abivax (ABVX) shares fell about 9.1% to $121.64 in midday U.S. trading on Monday, after touching $133.73 earlier in the session. The stock hit a low of $121.08, while its Paris-listed shares ended down 9.7%. Investing The pullback matters because Abivax has turned into a high-beta biotech name, where sentiment swings can be abrupt and outsized. Investors have been weighing a rich valuation built on late-stage trial hopes and deal chatter, and Monday’s drop tested how much of that optimism is still in the price. The move came as biotech
5 January 2026
··
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

New York, January 5, 2026, 10:58 (ET) — Regular session Eli Lilly and Company shares fell about 3.4% on Monday, extending early losses after rival Novo Nordisk began selling a pill version of its Wegovy weight-loss drug in the United States. The stock was down at $1,043.14 after dipping nearly 4% earlier in the session. The move puts the spotlight back on pricing power in obesity drugs, a market that has helped lift Lilly’s valuation and that investors treat as a multi-year growth engine. Novo said its once-daily Wegovy pill will start at $149 a month for self-paying patients, with
5 January 2026
···
Brand Engagement Network (BNAI) stock rises again premarket as AI pharma deal keeps traders hooked

Brand Engagement Network (BNAI) stock rises again premarket as AI pharma deal keeps traders hooked

NEW YORK, Jan 5, 2026, 06:59 ET — Premarket Shares of Brand Engagement Network, Inc (BNAI) rose 5.3% to $3.97 in premarket trading on Monday, extending a sharp late-week rally in the thinly traded AI company. Public The move keeps the stock on momentum screens after a burst of buying on Friday, when traders piled into small-cap AI names tied to contract headlines. With limited liquidity, the stock can swing quickly — especially in extended-hours trading outside the regular 9:30 a.m. to 4 p.m. session. Investors are focused on whether the company’s latest disclosed deal can translate into repeatable revenue.
5 January 2026
···
Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

NEW YORK, Jan 5, 2026, 06:09 ET — Premarket Ironwood Pharmaceuticals shares rose about 1% in premarket trading on Monday after Citizens upgraded the gastrointestinal drugmaker, arguing that pricing pressure on Linzess has eased. Citizens analyst Jason Butler wrote that “LINZESS headwinds have passed” as the stock traded at $4.32 at 6:01 a.m. ET; Wells Fargo also lifted its price target to $5 from $3. The shares closed up 26.7% on Friday at $4.27. Investing The broker moves follow Ironwood’s 2026 outlook built on Linzess, its bowel-disorder franchise sold in a U.S. collaboration with AbbVie. Ironwood on Friday forecast 2026
5 January 2026
··
GSK share price today: why the stock dipped after China approved Nucala for COPD

GSK share price today: why the stock dipped after China approved Nucala for COPD

LONDON, Jan 5, 2026, 09:46 GMT — Regular session GSK shares edged lower on Monday after the drugmaker said China’s medicines regulator approved its Nucala treatment for a form of chronic obstructive pulmonary disease (COPD). The stock was down about 0.3% at 1,825.5 pence by 09:45 GMT.  Investing The China nod matters because it opens a new label for one of GSK’s established respiratory drugs in a market where the company estimates around 100 million people have COPD. GSK said Nucala is the first and only monthly biologic approved in China and evaluated in COPD patients with blood eosinophil counts
5 January 2026
··
Merck stock in focus before Monday: Cidara deal deadline hits Jan. 6 as MRK sits near 52-week high

Merck stock in focus before Monday: Cidara deal deadline hits Jan. 6 as MRK sits near 52-week high

NEW YORK, Jan 4, 2026, 20:43 ET — Market closed Merck & Co shares closed up 1.1% on Friday at $106.45, leaving the stock within sight of a 52-week high ahead of Monday’s U.S. market reopen. MarketWatch The near-term focus is a tender offer — a takeover process where shareholders can sell stock directly for cash at a set price — tied to Merck’s planned purchase of Cidara Therapeutics. A Nasdaq corporate actions alert said the offer is scheduled to expire late Tuesday. NASDAQ Trader That timetable matters because it brings a catalyst into an otherwise light stretch for large-cap
5 January 2026
···
1 … 13 14 15 16 17 … 34

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Go toTop